Cart
sales@molnova.com
LX-6171
CAS No. 914808-66-5
LX-6171( —— )
Catalog No. M34323 CAS No. 914808-66-5
LX-6171, a proline transporter (SLC6A7) inhibitor, is used potentially for the treatment of schizophrenia and Alzheimer's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 221 | In Stock |
|
| 5MG | 205 | In Stock |
|
| 10MG | 302 | In Stock |
|
| 25MG | 489 | In Stock |
|
| 50MG | 695 | In Stock |
|
| 100MG | 977 | In Stock |
|
| 200MG | 1321 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLX-6171
-
NoteResearch use only, not for human use.
-
Brief DescriptionLX-6171, a proline transporter (SLC6A7) inhibitor, is used potentially for the treatment of schizophrenia and Alzheimer's disease.
-
DescriptionLX-6171, a proline transporter (SLC6A7) inhibitor, is used potentially for the treatment of schizophrenia and Alzheimer's disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number914808-66-5
-
Formula Weight377.87
-
Molecular FormulaC22H20ClN3O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESClC=1C=C(C2=CC=C(C(=O)C3CCN(CC3)C=4N=CC=CN4)C=C2)C=CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
MAGE-3 Antigen (271-...
MAGE-3 (271-279) is a 271-279 residue peptide derived from melanoma antigens encoded by MAGE-3. MAGE-3 is a cytolytic T lymphocyte (CTL)-defined MAGE-3 protein associated with the human leukocyte antigen (HLA)-A2 molecule. MAGE-3 is overexpressed in different human tumor types, including malignant melanoma, but not by normal tissues except for testis and placenta.
-
Raddeanoside 20
Raddeanoside 20 can slightly suppress the superoxide generation induced by N-formyl-methionyl-leucyl-phenylalanine (fMLP) in a concentration dependent manner.
-
(-)-Sparteine
Sparteine is a class 1a antiarrhythmic agent, a sodium channel blocker. The deficient debrisoquine hydroxylation of Sparteine is due to the absence of P-450IID1 protein in the livers of poor metabolizers.
